cv bourgeois-daigneault, marie-claude
TRANSCRIPT
Marie-‐Claude Bourgeois-‐Daigneault, Ph.D. 160 de Londres, #17 Phone Gatineau, (Quebec) (514) 268-‐7654 Canada, J9J 1K7 Date of birth: January 10th, 1985 Email address Bilingual: French and English [email protected]/[email protected] Career profile I am a Postdoctoral fellow with ten years of experience in basic research and teaching students scientific theory and technical skills. I have participated in more than two dozen national and international conferences. I am fascinated by science, more specifically the study of the immune system and cancer. I have specialized in oncolytic virotherapy, molecular immunology, biochemistry as well as cellular and molecular biology. I developed my mentoring skills by guiding numerous graduate students in the progression of their research projects. I am organized, independent, motivated and very collaborative. I write my own manuscripts and also have experience writing grants. I wish to pursue my career in the pre-‐clinical development, validation and characterization of cancer immunotherapeutic agents. Education 2013-‐Present Postdoctoral fellow; Microbiology and Immunology University of Ottawa; Ottawa, ON, Canada August 2014 Advanced Course of Immunology American Association of Immunologists; Boston, MA, USA 2008-‐2012 Ph.D.; Microbiology and Immunology Université de Montréal, Montreal, QC, Canada 2007-‐2008 Master’s; Microbiology and Immunology Université de Montréal, Montreal, QC, Canada 2004-‐2007 Undergraduate; Microbiology and Immunology Université de Montréal, Montreal, QC, Canada Research experience 2013-‐present Postdoctoral fellow, Immunology, Virology and cancer; Dr. John C. Bell; Ottawa Hospital Research Institute (Ottawa, ON) 2008-‐2012 Ph.D., Immunology; Dr. Jacques Thibodeau; Université de Montréal (Montreal, QC) 2007-‐2008 Master’s, Immunology; Dr. Jacques Thibodeau; Université de Montréal (Montreal, QC) 2007 Research trainee;
Co-‐supervision: Drs. Jacques Thibodeau and Daniel Lamarre; Université de Montréal and Institute for Research in Immunology and Cancer (Montreal, QC)
2006 Research trainee; Dr. Jacques Thibodeau; Université de Montréal (Montreal, QC) Industrial experience 2016 Study director; Combination of immune checkpoint inhibitors and oncolytic virus MG1 Turnstone Biologics; Ottawa, ON 2016 Consultant; Validation of novel recombinant viruses by flow cytometry Genvira Biosciences; Ottawa, ON
Specialization and specific skills
Tumor Immunology An immunologist by training, I learnt basic immunology techniques during my Ph.D. I specialized in tumor immunology during my postdoctoral fellowship.
Skills: Multi-‐color flow cytometry, ELISPOT and ELISA, immunohistochemistry, cytometric bead array, dissociation of various organs and tumor for analysis.
Immunotherapy Using oncolytic viruses, my focus has been to study the importance of the anti-‐tumor immune response for the virus efficacy. Skills: T cell transfer, in vivo cell depletion, immune checkpoint inhibitors blockade and anti-‐tumor vaccination.
In vivo work Studying cancer immunotherapy, I used a myriad of murine tumor models and techniques for treatment monitoring and efficacy studies. Skills: Tumor models (orthotopic, lung, subcutaneous and natural metastasis), injections (intratumoral, intramuscular, intranasal, intraperitoneal), analysis of tumor burden, oral gavage, tumor resection surgeries and in vivo imaging.
In vitro work I am familiar with the basic as well as more advanced biochemistry and cell biology techniques. Skills: Cell culture and transfection, viability assays, cloning, PCR and qPCR, exosome purification and analysis, virus production and characterization, cell cycle analysis, immunoprecipitation and western blot, confocal and electron microscopy, BRET and FRET.
Teaching Experience
Teaching experience; laboratories
2008-‐2012: Immunology Course – MCB3003; Université de Montréal 2006-‐2007: Microbiology Course – MCB1979; Université de Montréal Supervision and mentorship 2016-‐Present Dr. Carole Achard, Postdoctoral fellow with Dr. Guy Ungerechts – Close collaboration 2016-‐Present Dr. Barbara Ungerechts, Research associate with Dr. John Bell – Close collaboration 2015-‐Present Amelia Aitken, M.Sc. candidate with Dr. John Bell – Mentorship 2015-‐2016 Adrian Pelin, Ph.D. candidate with Dr. John Bell – Mentorship 2014-‐2016 Lauren St-‐Germain trainee with Dr. John Bell – Principal supervisor 2013-‐2016 Dominic Guy Roy, Ph.D. candidate with Dr. John Bell – Close collaboration 2013-‐2015 Monique Marguerie, M.Sc. candidate with Dr. John Bell – Mentorship 2014-‐2015 Vanessa Garcia, M.Sc. candidate with Dr. Jean-‐Simon Diallo – Mentorship 2014 Gregory Napier, trainee with Dr. John Bell – Principal supervisor 2014 Benjamin Engel, trainee with Dr. John Bell – Principal supervisor 2013-‐2014 Jovian Tsang, M.Sc. candidate with Dr. Harry Atkins – Mentorship 2013 Adamo Young and Sorush Rokui trainees with Dr. John Bell – Principal supervisor 2012 Anthony Chevrier. M.Sc. candidate with Dr. Jacques Thibodeau – Mentorship 2010 Maria Lopez trainee with Dr. Jacques Thibodeau – Principal supervisor 2009 Tristan Galbas , M.Sc. candidate with Dr. Jacques Thibodeau – Mentorship 2008 Jeanne Guenot, M.Sc. candidate with Dr. Jacques Thibodeau – Mentorship 2008 Caroline Landry trainee with Dr. Jacques Thibodeau – Principal supervisor 2007 Louis-‐David Rivard trainee with Dr. Jacques Thibodeau – Principal supervisor
Scholarships and Awards Scholarships 2015-‐2018 Postdoctoral fellowship; Canadian Institutes of Health Research ($40,000/year) 2015-‐2018 Postdoctoral fellowship; Fonds de recherche en Santé Québec ($35,000/year) -‐ Declined 2015-‐2018 Postdoctoral fellowship; Canadian Breast Cancer Foundation ($45,000/year) -‐ Declined 2011 Excellence award; Université de Montréal ($11,000) 2009-‐2011 Doctoral scholarship; The Cole foundation ($21,000/year) 2008-‐2009 Transfer to Ph.D award; Université de Montréal ($7,000/year) 2007 Scholarship for summer internship; COPSÉ ($4,250) 2006 Scholarship for summer internship; Rx&D ($4,250) Travel awards 2016; BioCanRx for the International Meeting on Replicating Oncolytic Virus Therapeutics ($1,500) 2016; BioCanRx for the Summit for Cancer Immunotherapy (2,000$) 2013; Canadian Society for Immunology for the International Congress of Immunology, Italy ($1,500) 2013; Canadian Society for Immunology (CSI) for the CSI Annual Conference ($500) 2010; Cole Foundation for the International Congress of Immunology, Japan ($3,500) 2008; Immunology Montreal for the Canadian Society for Immunology Conference ($500) Awards 2009; 2nd place, oral presentation; Université de Montréal ($500) 2007; 2nd place, oral presentation; Institut Armand-‐Frappier ($1,000) Publications In preparation – manuscripts available upon request 1-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Aitken A.S, Falls T, St-‐Germain L.E, Pelin A, Ungerechts G and Bell J.C. Use of oncolytic virotherapy to heat-‐up immune checkpoint blockade-‐refractory tumors in a window of opportunity study for triple-‐negative breast cancer. 2-‐ Roy D.G, Bourgeois-‐Daigneault M.C, Pelin A, Varble A, Singaravelu R.A, Davis C, Falls T, Petryk J, Pezacki J.P, TenOever B.R and Bell J.C. RNAi screen in tumor cells reveals artificial microRNAs that improve oncolytic virus replication. In revision – manuscripts available upon request 1 – Sennino B, Nitschke M, Schriver, B.J, McDonald C.E, Murer P, Bell A, De Silva N, Bourgeois-‐Daigneault M.C, Bell J.C, Kirn D, Breitbach C and McDonald D.M. Synergistic actions of oncolytic vaccinia virus combined with sunitinib in pancreatic neuroendocrine cancer. In revision – Cancer Research. Published peer-‐reviewed papers
1-‐ Veinalde R, Grossardt C, Hartmann L, Bourgeois-‐Daigneault M.C, Bell J.C, Jäger D, von Kalle C, Ungerechts G and Engeland C.E. Oncolytic measles virus encoding interleukin-‐12 mediates potent anti-‐tumor effects through activation of natural killer and T cell responses. OncoImmunology 2017.
2-‐ Aitken A, Roy D and Bourgeois-‐Daigneault M.C*. Taking a stab at cancer ; Oncolytic virus-‐mediated anti-‐cancer vaccination strategies. Biomedicines 2017. *Corresponding author
3-‐ Galbas T, Raymond M, Sabourin A, Bourgeois-‐Daigneault M.C, Guimont-‐Desrochers F, Jin T, Cailhier J.F, Ishido S, Lesage S, Cheong C and Thibodeau J. MARCH1 dampens the innate immune response by modulating monocytes function. Journal of Immunology 2017.
4-‐ Evgin L, Ilkow C.S, Bourgeois-‐Daigneault M.C, de Souza C, Stubbert L, Jennings V.A, Marguerie M, Acuna S, Keller B, Lefebvre C, Falls T, Le Bœuf F, Auer R, Lambris J, McCart J.A, Stojdl D.F and Bell J.C. Inhibition of complement activity enables repeat administration of LCMV glycoprotein pseudotyped therapeutic viruses. Molecular Therapy Oncolytics 2016.
5-‐ Nagarajan A, Petersen M.C, Nasiri A.R, Butrico G, Fung A, Ruan H.B, Kursawe R, Caprio S, Thibodeau J, Bourgeois-‐Daigneault M.C, Sun L, Gao G, Bhanot S, Jurczak M.J, Green M.R, Shulman G.I and Wajapeyee N. MARCH1 regulates insulin sensitivity by controlling cell surface insulin receptor levels. Nature Communications 2016.
6-‐ Bourgeois-‐Daigneault M.C*, St-‐Germain L.E, Roy D.G, Pelin A, Aitken A.S, Arulanandam R, Falls T, Garcia V, Diallo J.S and Bell J.C. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Research 2016. *Corresponding author
7-‐ Falls T, Roy D.G, Bell J.C and Bourgeois-‐Daigneault M.C*. Murine Tumor Models for Oncolytic Rhabdo-‐Virotherapy. ILAR Journal 2016. *Corresponding author
8-‐ Bourgeois-‐Daigneault M.C*, Roy D.G, Falls T, Twumasi-‐Boateng K, St-‐Germain L.E, Marguerie M, Garcia V, Selman M, Jennings V.A, Pettigrew J, Amos S, Diallo J.S, Nelson B and Bell J.C. Oncolytic vesicular stomatitis virus expressing interferon-‐γ has enhanced therapeutic activity. Molecular Therapy-‐Oncolytics 2016. *Corresponding author
9-‐ Roy D.G, Power A.T, Bourgeois-‐Daigneault M.C, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart J.A, Stojdl D.F, Lichty B.D, Atkins H, Auer R.C, Bell J.C and Le Boeuf F. Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy. Journal of Controlled Release 2015.
10-‐ Arulanandam R, Batenchuk C, Angarita F.A, Ottolino-‐Perry K, Cousineau S, Mottashed A, Burgess E, Falls T.J, De Silva N, Tsang J, Howe G.A, Bourgeois-‐Daigneault M.C, Conrad D.P, Daneshmand M, Breitbach C.J, Kirn D.H, Raptis L, Sad S.], Atkins H, Huh M.S, Diallo J.S, Lichty B.D, Ilkow C.S, Le Boeuf F, Addison C.L, McCart J.A and Bell J.C. VEGF-‐Mediated Induction of PRD1-‐BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell 2015.
11-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Identification of a novel motif that affects the conformation and activity of the MARCH1 E3 ubiquitin ligase. Journal of Cell Science 2013.
12-‐ Bourgeois-‐Daigneault M.C, Pezeshki A.M, Galbas T, Houde M, Baril M, Früh K, Amrani A, Ishido S, Lamarre D and Thibodeau J. Tollip-‐induced down-‐regulation of MARCH1. Results in Immunology 2013.
13-‐ Finzi A, Perlman M, Bourgeois-‐Daigneault M.C, Thibodeau J and Cohen E.A. MHC-‐II molecules promote targeting of HIV-‐1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. Cellular Microbiology 2013.
14-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Autoregulation of MARCH1 expression by dimerization and autoubiquitination. Journal of Immunology 2012.
15-‐ Thibodeau J, Bourgeois-‐Daigneault M.C and Lapointe R. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. OncoImmunology 2012.
16-‐ Xiu F, Cote M. H*, Bourgeois-‐Daigneault M.C*, Brunet A, Gauvreau M.É, Shaw A. and Thibodeau J. Cutting edge: HLA-‐DO impairs the incorporation of HLA-‐DM into exosomes. Journal of Immunology 2011. * these authors contributed equally
17-‐ Thibodeau J, Bourgeois-‐Daigneault M.C and Lapointe, R. Counteracting subversion of MHC class II antigen presentation by tumors. Experimental and Applied Immunotherapy 2011 -‐ book chapter.
18-‐ Gauvreau M.E, Côté M.H*, Bourgeois-‐Daigneault M.C*, Rivard L.D, Xiu F, Brunet A, Shaw A, Steimle V and Thibodeau J. Sorting of MHC class II molecules into exosomes through a ubiquitin-‐independent pathway. Traffic 2009. * these authors contributed equally
19-‐ Thibodeau J, Bourgeois-‐Daigneault M.C, Huppe G, Tremblay J, Aumont A, Houde M, Bartee E, Brunet A, Gauvreau M.E, de Gassart A, Gatti E, Baril M, Cloutier M, Bontron S, Früh K, Lamarre D and Steimle V. Interleukin-‐10-‐induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. European Journal of Immunology 2008.
Oral presentations
1-‐ Bourgeois-‐Daigneault M.C and Bell J.C. Oncolytic virus Maraba-‐MG1-‐mediated immunotherapy. Symposium International des Jeunes Chercheurs de l’IRIC. Montreal, Canada 2017.
2-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Aitken A, Falls T and Bell J.C. Oncolytic virus-‐mediated immunotherapy. The Ottawa Hospital Research Institute Research Day. Ottawa, Canada 2016.
3-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Aitken A, Falls T and Bell J.C. Oncolytic virus-‐mediated immunotherapy. The International Meeting on Replicating Oncolytic Virus Therapeutics. Vancouver, Canada 2016.
4-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Falls T and Bell J.C. Oncolytic virus-‐mediated immunotherapy. The International Congress of Immunology. Melbourne, Australia 2016.
5-‐ Bourgeois-‐Daigneault M.C, Le Boeuf F. and Bell J.C. Differential response to oncolytic virotherapy in primary tumors versus metastases. Canadian Oncolytic Virus Consortium annual meeting. Rideau Lakes, Canada 2014.
6-‐ Bourgeois-‐Daigneault M.C and Thibodeau, J. Autorégulation de l’expression et de la fonction de MARCH1, une E3 ubiquitin ligase par dimérisation et autoubiquitination. Research day, University of Montreal. Montreal, Canada 2009.
7-‐ Bourgeois-‐Daigneault M.C, Huppé G, Steimle V and Thibodeau J. Molecular interaction between MARCH-‐1, an E3 ubiquitin ligase, and HLA-‐DR prevents antigen presentation in response to IL-‐10. The Canadian Society for Immunology. Mont-‐Tremblant, Canada 2008.
8-‐ Bourgeois-‐Daigneault M.C, and Thibodeau J. Implication de MARCH-‐1 et MARCH-‐8 dans la régulation de la présentation antigénique. COPSÉ. Montreal, Canada 2008.
9-‐ Bourgeois-‐Daigneault, M.C, Huppé G, Steimle V and Thibodeau J. MARCH1 induit par l’interleukine-‐10 médie la séquestration intracellulaire du CMH de classe II dans les monocytes. Institut Armand-‐Frappier. Bromont, Canada 2007.
10-‐ Bourgeois-‐Daigneault, M.C and Thibodeau J. Régulation du ciblage intracellulaire de HLA-‐DR par l’ubiquitine ligase I3.4. COPSÉ. Montreal, Canada 2007.
Poster presentations
1-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Falls T and Bell J.C. Oncolytic virus-‐mediated immunotherapy. Summit for cancer immunotherapy. Halifax, Canada 2016.
2-‐ Bourgeois-‐Daigneault M.C, Roy D.G, St-‐Germain L.E, Falls T and Bell J.C. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. The Ottawa Hospital Research Institute research day. Ottawa, Canada 2015.
3-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Falls T. Nelson B and Bell J.C. An Interferon-‐gamma expressing oncolytic virus demonstrates improved efficacy in various tumor models. 9th International conference on oncolytic virus therapeutics. Boston, USA 2015.
4-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Falls T. Nelson B and Bell J.C. IFNγ-‐armed oncolytic virus for cancer treatment. Canadian Cancer Immunotherapy Consortium. Vancouver, Canada 2015.
5-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Falls T, Marguerie M and Bell J.C. Oncolytic viruses for immunotherapy. Tumor Immunology-‐Keystone symposia. Banff, Canada 2015.
6-‐ Bourgeois-‐Daigneault M.C, Roy D.G, Marguerie M, Falls T and Bell J.C. Generation of tumor-‐specific immune responses by oncolytic virotherapy. The Ottawa Hospital Research Institute research day, Ottawa, Canada 2014.
7-‐ Bourgeois-‐Daigneault M.C, Roy D.G and Bell J.C. Generation of tumor-‐specific immune responses and reversion of tumor-‐driven immune suppression by oncolytic virus treatment. Cancer Immunotherapy; out of the gate; Cancer Research Institute. New-‐York, USA 2014.
8-‐ Bourgeois-‐Daigneault M.C, Roy D.G and Bell J.C. Cytometric Bead Array as a tool to detect transgene expression and anti-‐viral response to oncolytic viruses. The University of Ottawa Flow Cytometry symposia. Ottawa, Canada 2014.
9-‐ Bourgeois-‐Daigneault M.C, Pezeshki A.M and Thibodeau J. Tollip-‐induces down-‐regulation of MARCH1. The International Congress of Immunology. Milan, Italy 2013.
10-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Identification of a novel motif in MARCH1 that affects the conformation and the E3 ubiquitin ligase activity. The American Association of Immunologists. Boston, USA 2012.
11-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Identification of a novel motif in MARCH1, an E3 ubiquitin ligase, that influences the conformation and the activity of the molecule. Canadian Cancer Immunotherapy Consortium. Montreal, Canada 2012.
12-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Inhibition of aerobic glycolysis by MARCH1. The Cole foundation research day. Montreal, Canada 2011.
13-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Regulation of MARCH1 expression and function through dimerization and autoubiquitination. The International Congress of Immunology. Kobe, Japan 2011.
14-‐ Bourgeois-‐Daigneault M.C and Thibodeau J. Implication of MARCH family members in development and progression of acute type leukemias. The Cole foundation research day. Montreal, Canada 2010.
15-‐ Bourgeois-‐Daigneault M.C. and Thibodeau J. Régulation de l’expression et de la fonction de MARCH1, une E3 ubiquitine ligase, par dimerization et autoubiquitination. Institut Armand-‐Frappier. Bromont, Canada 2009.
16-‐ Bourgeois-‐Daigneault M.C and Thibodeau, J. Regulation of MARCH1 function through dimerization and ubiquitination. The Ubiquitin Family. New-‐York, USA 2009.
17-‐ Bourgeois-‐Daigneault M.C, Huppé G, Steimle V and Thibodeau J. Molecular mechanisms of MHC class II inhibition by the MARCH1 ubiquitin ligase in response to IL-‐10. Cytokine. Montreal, Canada 2008.
18-‐ Bourgeois-‐Daigneault M.C, Huppé G, Steimle V and Thibodeau J. Molecular interaction between MARCH-‐1, an E3 ubiquitin ligase, and HLA-‐DR prevents antigen presentation in response to IL-‐10. The Canadian Society for Immunology. Mont-‐Tremblant, Canada 2008.
Organization
2013-‐present The Ottawa Hospital Research Institute Journal Club program; Coordinator 2013-‐present Fund raising for the Terry Fox Foundation; Organizer and volunteer November 2015 Scientific retreat, Ottawa oncolytic virus groups; Organizer